Sequenex Teams Up With MedTech Innovator

Sequenex today announced its partnership with MedTech Innovator (MTI), the world’s largest accelerator of medical technology companies. MedTech Innovator matches healthcare industry leaders with innovative early-stage medtech companies for mentorship and support. This year, MedTech Innovator is slated to select 65 startups for participation in its program.

Sequenex will work directly with select emerging companies and provide financial support to MedTech Innovator. Through this partnership, Sequenex will support early- and growth-stage medtech companies by providing scalable, regulatory-ready software solutions for connected medical devices, including CGM, biosensors, and wearables. By drawing on its expertise in compliant software development and leveraging its prebuilt, customizable NEX platform, Sequenex aims to accelerate development, streamline regulatory readiness, and help innovators bring transformative medical technologies to market more efficiently.

“Partnering with MedTech Innovator aligns perfectly with our mission to remove barriers to innovation in connected medical devices,” Sequenex Chief Technology Officer John Krlin said. “Many startups are building groundbreaking technologies but face significant challenges when it comes to software development, integration, and regulatory readiness. We’re excited to provide the tools and expertise needed to help these companies move faster and bring impactful solutions to patients.”

As a partner, Sequenex will engage with MedTech Innovator at every critical inflection point throughout the year. Reviewers and judges face a formidable task, with MTI receiving a record-setting 1,800 applications for this year’s program. The top 10% of applicants advanced to the Radar Forum, held in early April in Manhattan Beach and virtually, earning an opportunity to pitch and engage with the MTI ecosystem.

“I’m proud of our longstanding success in discovering and supporting the world’s most promising medical technology and digital health companies,” MedTech Innovator Founder/CEO Paul Grand stated. “Our carefully curated partners and sponsors serve a vital role in driving innovations to achieve their maximum potential, and we are thrilled to welcome Sequenex as our newest partner. Together, we look forward to improving patient outcomes and creating lasting value across the healthcare ecosystem.”

Following final cohort selection in May, the 2026 accelerator officially launched at the invite-only Innovator Summit in early June in San Francisco, where companies from the latest cohorts convened with hundreds of representatives from MTI’s partners, mentors, and alumni. The program will culminate in October at the Finals Competitions, where partners reconnect with the cohort as companies showcase their progress and readiness for partnership and investment.

Sequenex is a software and product development firm focused on connected medical devices, biosensors, and continuous glucose monitoring (CGM) technologies. Through its prebuilt and configurable NEX platform, Sequenex accelerates the delivery of mobile, cloud, and device-integrated applications. Operating under an ISO 13485–certified Quality Management System, Sequenex develops medtech software in accordance with IEC 62304 and ISO 14971, supporting the full product lifecycle from prototype to clinical and commercial systems. Its approach combines a reusable software foundation with custom development to enable rapid device integration while maintaining a clear path to regulatory submission.

MedTech Innovator is the world’s largest accelerator of medical device, digital health, and diagnostic companies. Its mission is to improve human health by accelerating the growth of companies transforming patient care. MTI has been a catalyst for healthcare solutions, sourcing more than 15,000 applicants and fostering the growth of 838 graduates. Alumni have collectively raised $11 billion in follow-on funding and introduced 500-plus products to the market.